<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04791800</url>
  </required_header>
  <id_info>
    <org_study_id>8820-2/1</org_study_id>
    <nct_id>NCT04791800</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of the STANDARD™ Q Malaria/CRP Duo Test</brief_title>
  <official_title>Evaluation of the Clinical Performance of the STANDARD™ Q Malaria/CRP Duo Test (SD Biosensor, South Korea) for the Diagnosis of Malaria and the Detection of C-reactive Protein (CRP) in Fingerprick Blood of Febrile Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foundation for Innovative New Diagnostics, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Malaria Research, New Delhi, India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Foundation for Innovative New Diagnostics, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the clinical performance (sensitivity, specificity,&#xD;
      positive and negative predictive values) of the STANDARD™ Q Malaria/CRP Duo Test when used by&#xD;
      health care workers (HW) in a point of care (POC) setting in malaria endemic areas in India.&#xD;
      Performance will be assessed in comparison with expert microscopy as the reference test for&#xD;
      malaria, and with a high quality, commercially available C-Reactive Protein (CRP) test kit&#xD;
      run on a laboratory machine as a reference test for CRP.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 8, 2019</start_date>
  <completion_date type="Actual">September 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 16, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical performance of the Malaria/CRP combination test for malaria diagnosis at day 0</measure>
    <time_frame>Day 0</time_frame>
    <description>Point estimates (with 95% confidence intervals) of the sensitivity, specificity, positive and negative predictive values of the STANDARD™ Q Malaria/CRP Duo Test for the diagnosis of malaria, in comparison with expert microscopy as the reference test at day 0 (first day of presentation).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical performance of the Malaria/CRP combination test for detection of high levels of C-reactive protein at day 0</measure>
    <time_frame>Day 0</time_frame>
    <description>Point estimates (with 95% confidence intervals) of the sensitivity, specificity, positive and negative predictive values of the STANDARD™ Q Malaria/CRP Duo Test for the detection of CRP at day 0, in comparison with the CRP-LX reagent kit used with the Roche Diagnostics Cobas™ c111 chemistry analyser, or equivalent, as the reference test.</description>
  </primary_outcome>
  <enrollment type="Actual">1808</enrollment>
  <condition>Fever Malaria</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Malaria/CRP combination test</intervention_name>
    <description>Testing with a malaria/CRP combination test, in parallel with a standard malaria RDT (to guide case management), preparation of thin/thick films for expert malaria microscopy, and collection of venous blood for subsequent CRP quantification.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged 5 years and above with clinically suspected malaria on the basis of fever or&#xD;
        history of fever in the previous 72 h, either enrolled by passive case detection in health&#xD;
        care facilities, or by active case detection in the surrounding communities.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  clinically suspected malaria on the basis of fever or history of fever in the previous&#xD;
             72 h&#xD;
&#xD;
          -  age ≥ 5 years, (iii) having been informed of the study and signed a written consent&#xD;
             form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  signs of severe malaria or other severe disease&#xD;
&#xD;
          -  patients not fulfilling the inclusion criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Anupkumar Anvikar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Malaria Research, New Delhi, India</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NIMR</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 10, 2020</study_first_submitted>
  <study_first_submitted_qc>March 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>malaria</keyword>
  <keyword>fever</keyword>
  <keyword>C-reactive protein</keyword>
  <keyword>point-of-care testing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

